Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)
- Registration Number
- NCT01114490
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Female subjects of reproductive potential test negative for pregnancy and agree to use two acceptable methods of birth control throughout the study
- Subject is in good health
- Subject agrees to refrain from consumption of red wine, grapefruit, orange and apple juices throughout the study
Exclusion Criteria
- Patient has a history of cancer
- Patient is a nursing mother
- Patient is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study
- Patient consumes excessive amounts of alcohol or caffeine
- Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 1 - Group 1 anacetrapib Moderate Hepatic Patients Part 1 - Group 2 anacetrapib Healthy Subjects Part 2 - Group 1 anacetrapib Mild Hepatic Patients Part 2 - Group 2 anacetrapib Healthy Subjects
- Primary Outcome Measures
Name Time Method Area Under the Curve (AUC(0 to infinity)) of anacetrapib through 168 hours post dose
- Secondary Outcome Measures
Name Time Method Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events through 14 days post dose